Valneva’s management team is now free to sell shares after a 61-day lock-up period expired on Tuesday, potentially adding further pressure to a stock already trading near its 52-week low. The restriction was tied to an April capital raise that brought in EUR 84 million through the issuance of roughly 16 million new shares at EUR 2.33 apiece, and its lifting comes at a time when the vaccine developer’s equity has been under relentless selling pressure.
The shares closed Monday at EUR 2.26, barely above the February trough of EUR 2.13. Since the start of the year the stock has shed about 41% of its value, and the technical picture remains grim. The 200-day moving average sits at EUR 3.60 – far above any near-term recovery hopes – while the 50-day line at EUR 2.41 has already been breached. The relative strength index stands at 37.6, creeping toward oversold territory but without a clear reversal signal.
The capital injection from April was intended to fund the expansion of Valneva’s vaccine pipeline and its commercial operations, yet it has done little to stem the slide. First-quarter 2026 results, released in the meantime, did not help: the company reported a loss per share of USD 0.42 on revenue of roughly USD 35.8 million. Management has set a full-year revenue target of EUR 135 million to EUR 150 million, an ambitious goal given the slow start.
Should investors sell immediately? Or is it worth buying Valneva?
Analyst opinion is sharply divided. Goldman Sachs recommends selling the company’s US-listed ADRs, with a price target of USD 4.90. Guggenheim, by contrast, stays bullish with an USD 11 target and a buy rating. The consensus sits at “hold” with an average target of nearly USD 12 – a level that now looks distant given the current EUR-equivalent price of around USD 2.40 per ADR share.
For now, the stock’s biggest hope rests on a totally different front: the Lyme disease vaccine candidate developed with Pfizer. Late-stage data showed over 70% efficacy, and Valneva plans to submit a filing with the FDA. With more than 470,000 Lyme cases reported annually in the US and no approved vaccine on the market, the potential is undeniable. Early-stage data on other candidates, including an antibody therapy, have also shown tolerability. The FDA submission is widely seen as the single most important catalyst for the stock – but any delays could deepen the gloom.
With the insider lock-up now behind them, the risk of additional share supply hitting the market is real. If Valneva’s own executives decide to sell, the EUR 2.13 support level will come under immediate threat. Breaking that floor would send the stock into uncharted low ground, amplifying the already entrenched downtrend.
Ad
Valneva Stock: Buy or Sell?! New Valneva Analysis from June 30 delivers the answer:
The latest Valneva figures speak for themselves: Urgent action needed for Valneva investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 30.
Valneva: Buy or sell? Read more here...
